Christopher N Bredeson
Overview
Explore the profile of Christopher N Bredeson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gooptu M, Romee R, Martin A, Arora M, Al Malki M, Antin J, et al.
Blood
. 2021 Jul;
138(3):273-282.
PMID: 34292325
Posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis has enabled haploidentical (Haplo) transplantation to be performed with results similar to those after matched unrelated donor (MUD) transplantation with traditional prophylaxis. The...
2.
Grunwald M, Zhang M, Elmariah H, Johnson M, Martin A, Bashey A, et al.
Blood Adv
. 2021 Feb;
5(4):975-983.
PMID: 33576783
We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA-haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplantation (HCT) from 2012 to...
3.
Alousi A, Wang T, Hemmer M, Spellman S, Arora M, Couriel D, et al.
Biol Blood Marrow Transplant
. 2018 Oct;
25(2):270-278.
PMID: 30292009
Peripheral blood (PB) and bone marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation (HCT). Currently, PB is most commonly used in roughly 80%...
4.
Gajewski J, McClellan M, Majhail N, Hari P, Bredeson C, Maziarz R, et al.
Biol Blood Marrow Transplant
. 2017 Oct;
24(1):4-12.
PMID: 28963077
Patient-centered medical home models are fundamental to the advanced alternative payment models defined in the Medicare Access and Children's Health Insurance Plan Reauthorization Act (MACRA). The patient-centered medical home is...
5.
Stroncek D, Shaw B, Logan B, Kiefer D, Savani B, Anderlini P, et al.
Biol Blood Marrow Transplant
. 2017 Sep;
24(1):175-184.
PMID: 28958894
Little is known about the experiences of individuals donating peripheral blood stem cells (PBSCs) or marrow for a second time. To study this, unrelated donors making a second donation through...
6.
Rizk M, Monaghan M, Shorr R, Kekre N, Bredeson C, Allan D
Biol Blood Marrow Transplant
. 2016 May;
22(8):1416-1423.
PMID: 27130504
Effective treatments are lacking for the treatment of steroid-refractory graft-versus-host disease (GVHD), a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. Mesenchymal stromal cells (MSCs) have demonstrated...
7.
Majhail N, Farnia S, Carpenter P, Champlin R, Crawford S, Marks D, et al.
Biol Blood Marrow Transplant
. 2015 Aug;
21(11):1863-1869.
PMID: 26256941
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. With advances in transplantation technology and supportive care practices, HCT has become safer, and patient survival...
8.
Khera N, Majhail N, Brazauskas R, Wang Z, He N, Aljurf M, et al.
Biol Blood Marrow Transplant
. 2015 Jun;
21(10):1815-22.
PMID: 26071866
Controversy surrounds the question of whether clinical trial participants have better outcomes than comparable patients who are not treated on a trial. We explored this question using a recent large,...
9.
Urbano-Ispizua A, Pavletic S, Flowers M, Klein J, Zhang M, Carreras J, et al.
Biol Blood Marrow Transplant
. 2015 May;
21(10):1746-53.
PMID: 25981509
The purpose of this study was to analyze the impact of graft-versus-host disease (GVHD) on the relapse rate of different lymphoma subtypes after allogeneic hematopoietic cell transplantation (allo-HCT). Adult patients...
10.
Holter-Chakrabarty J, Pierson N, Zhang M, Zhu X, Akpek G, Aljurf M, et al.
Biol Blood Marrow Transplant
. 2015 Apr;
21(7):1251-7.
PMID: 25840335
Limited clinical data are available to assess whether the sequencing of cyclophosphamide (Cy) and total body irradiation (TBI) changes outcomes. We evaluated the sequence in 1769 (CyTBI, n = 948;...